Brivaracetam original drug information and market status analysis

Brivaracetam is a new generation anti-epileptic drug mainly used for the adjuvant treatment of partial-onset epilepsy in adults and adolescents. As a structural analogue of levetiracetam (Levetiracetam), brivaracetam has more optimized pharmacodynamics and pharmacokinetics, especially in terms of speed of onset of action and brain targeting. The drug was developed by the Belgian pharmaceutical company UCB and is an important new anti-epileptic drug launched by the company after levetiracetam.

The brand name of the original drug isBriviact®. It was first approved in Europe in 2016 and was subsequently launched in the United States, Japan and other countries and regions. Briviact®has good safety and tolerability. It mainly stabilizes neuronal activity by selectively binding to synaptic vesicle protein 2A (SV2A) in the brain. Compared with levetiracetam, brivaracetam has higher affinity and fewer central nervous system side effects, especially in terms of mental and behavioral reactions such as anxiety and irritability.

In terms of market status, Brivaracetam has been marketed in many countries around the world and has been gradually included in local medical insurance catalogs, with drug coverage continuing to expand. In the domestic market, so far, Brivaracetam has been approved for marketing by the State Food and Drug Administration, and the original research product is provided by UCB Company. However, since it is an imported original drug, the price is relatively high, and the coverage of medical insurance and the number of hospital purchases are still being gradually improved.

In addition, there are currently no generic drugs of Brivaracetam officially launched in China, so the market is still dominated by the original drug. As epilepsy patients' demand for higher-quality treatment increases, brivaracetam is expected to occupy a more important position in the anti-epileptic drug market with its good efficacy and side-effect control capabilities, especially in the field of treatment of refractory epilepsy. It has great development potential. In the future, if domestic generic drugs or more cost-effective versions are launched, it will help further expand patient accessibility.

Reference materials:https://www.drugs.com/